Harvard Bioscience, Inc. (HBIO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Axogen, Inc.

Bioventus, Inc.

TELA Bio, Inc.

908 Devices, Inc.

Harvard Bioscience, Inc.

Butterfly Network, Inc.

Standard BioTools, Inc.

Allurion Technologies, Inc.

Celcuity, Inc.

Pulse Biosciences, Inc.

Jin Medical International Ltd.

Why is Harvard Bioscience, Inc. ?

Poor Management Efficiency with a low ROCE of 0.93%

The company has been able to generate a Return on Capital Employed (avg) of 0.93% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -3.39% over the last 5 years

Positive results in Jun 25

NET PROFIT(HY) Higher at USD -4.21 MM
RAW MATERIAL COST(Y) Fallen by 1.51% (YoY)
CASH AND EQV(HY) Highest at USD 12.99 MM

Risky - Negative Operating Profits

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -66.96%, its profits have fallen by -34.3%

High Institutional Holdings at 70.3%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -66.96% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Harvard Bioscience, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Harvard Bioscience, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Harvard Bioscience, Inc.

-67.73%

-0.42

176.74%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-3.39%

EBIT Growth (5y)

-30.19%

EBIT to Interest (avg)

-0.06

Debt to EBITDA (avg)

7.24

Net Debt to Equity (avg)

2.15

Sales to Capital Employed (avg)

1.12

Tax Ratio

0.13%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

70.30%

ROCE (avg)

0.93%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.22

EV to EBIT

-10.53

EV to EBITDA

23.59

EV to Capital Employed

1.07

EV to Sales

0.55

PEG Ratio

Dividend Yield

ROCE (Latest)

-10.16%

ROE (Latest)

-61.48%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

NET PROFIT(HY)

Higher at USD -4.21 MM

RAW MATERIAL COST(Y)

Fallen by 1.51% (YoY

CASH AND EQV(HY)

Highest at USD 12.99 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 7.27 times

-8What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD 6.19 MM

ROCE(HY)

Lowest at -138.36%

DEBT-EQUITY RATIO (HY)

Highest at 228 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.82 times

NET SALES(Q)

Lowest at USD 20.45 MM

Here's what is working for Harvard Bioscience, Inc.

Net Profit

Higher at USD -4.21 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Cash and Eqv

Highest at USD 12.99 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debtors Turnover Ratio

Highest at 7.27 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 1.51% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Harvard Bioscience, Inc.

Operating Cash Flow

Lowest at USD 6.19 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Sales

Lowest at USD 20.45 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Net Sales

At USD 20.45 MM has Fallen at -10.5%

over average net sales of the previous four periods of USD 22.85 MM

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Debt-Equity Ratio

Highest at 228 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.82 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio